Medindia

X

PharmaNet Development Group Hosts Phase IV Symposium in London on June 3, 2010

Wednesday, May 12, 2010 Press Release J E 4
Advertisement
PRINCETON, N.J., May 11 PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, is pleased to announce that it is hosting a complimentary symposium entitled "Safety and Value: Critical Success Factors for Post-Approval Research" at the Royal College of Surgeons in London, United Kingdom on June 3, 2010.

Post-approval studies are essential in characterizing the real-world performance of medical products in terms of safety, effectiveness, economic value and quality of life. During this symposium, industry leaders will join PharmaNet experts to discuss techniques to optimize post-approval research including:

Please contact Andrew Ecob at aecob@pharmanet.com or +1 44 1494 560 426 for more information or to attend the event. Space is limited.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees in 34 counties and 42 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.

-- Strategic Post-Approval Research Planning, Jeff Trotter, Executive Vice President, Phase IV Development, PharmaNet

SOURCE PharmaNet Development Group, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
FDA Approves Cefepime for Use In B. Braun's DUPLEX...
S
IVT Will Demo the World's First 3G based mHealth S...